Von Willebrand factor (VWF) is a plasma glycoprotein that can bind collagen at a wound site as well as circulating platelets. VWF forms high molecular weight multimers (>20,000 kDa).
Von Willebrand Factor
Von Willebrand Factor (VWF) is a plasma glycoprotein that binds collagen at a wound site, and also bind to circulating platelets. VWF is only generated from two cell types: megakaryocytes (and subsequently, platelets) and endothelial cells (1) . The synthesis of the protein is atypical in that it forms dimers in the endoplasmic reticulum and is then processed into multimers in the Golgi (1) . Multimers, the mature form of VWF, are long chains of VWF dimers connected by disulfide bridges (2, 3) . VWF multimers are highly thromboactive and can exceed 20,000 kDa (4) . VWF is also able to form long tethers that are attached to the endothelial surface called "VWF strings" (5, 6) . These strings were originally identified in vitro on the surface of cultured endothelial cells following the addition of the endothelial agonist, histamine. These strings were found to be as long as a few hundred micrometers and were shown to bind numerous platelets via GpIbα in vitro (5, 7) . These strings are rapidly cleaved in the presence of ADAMTS13, a VWF-cleaving plasma metalloprotease (2, 5, 8, 9) . Deficiency in ADAMTS13 has been correlated with thrombotic thrombocytopenic Purpura (TTP) (9) (10) (11) (12) (13) (14) . ADAMTS13, which is primarily derived from liver hepatic stellate cells, cleaves VWF at a conserved region between Tyr1605 and Met1606, and can only do so under shear stress due to folding constraints on VWF (1, 2, 15) . Currently, no other substrates or functions for ADAMTS13 have been identified (2, 9, 12, 15, 16) .
Thrombotic Thrombocytopenic Purpura
Severe ADAMTS13 deficiency in humans is associated with the pathology of TTP, a rare disease of inappropriate blood clotting. TTP is clinically identified by a pentad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, renal dysfunction, neurological dysfunction and fever (9, 17, 18) . Histologically, TTP is characterized by VWF-and platelet-rich thrombi in the microvasculature of organs throughout the body (18) . Analysis of blood smears collected from TTP patients reveals the presence of schistocytes (19) . Complete blood count analysis identifies the thrombocytopenia and anemia (19) . Even with modern treatment methods, mortality approaches 20%. Many decades after TTP's initial description in 1924, it was determined that TTP is directly related to a deficiency of function in ADAMTS13 (20) .
Typically, TTP manifests as an acquired autoimmune inhibition of ADAMTS13 (<5% of normal function (1, 13, 21, 22) ). There are also genetic presentations of TTP; mutations in the gene coding for ADAMTS13 most commonly lead to defects in its secretion (10) .
Murine Model of TTP
In order to model TTP, an ADAMTS13 knockout mouse was developed (8) . This mouse demonstrates all of the hallmarks of human acquired TTP, including spontaneous development of TTP, schistocytes in blood smears, VWF-rich occlusive thrombi in the microvasculature, thrombocytopenia, and microangiopathic hemolytic anemia (8) . However, having the disease develop spontaneously makes this a difficult model to study. It was determined that TTP could be triggered acutely in these mice by injecting E. Coli-derived shigatoxin, a known potent endothelial activator (8) . Being able to temporally control the disease onset means that the disease can be studied in more controlled circumstances. In addition, the advent of the Adamts13 -/-mouse lead to the first discovery of VWF strings in vivo (8) . These strings appear to bind platelets similarly to VWF strings formed in vitro. This model provides a powerful tool to ask questions about TTP and the nature of VWF strings in vivo.
Early experiments with this mouse model determined that VWF is an essential protein in TTP pathogenesis (23) . However conclusive, these experiments did not address bigger mechanistic questions of the disease; while it is clear that VWF is necessary, it was unclear what role, if any, VWF strings play in the pathogenesis of the disease.
Research Focus
While it is clear that VWF is essential in TTP pathogenesis (23) , how it regulates disease progression and leads to the formation of the thrombi characteristic of TTP is largely unknown.
Moreover, it is unknown what role, if any, VWF strings play in TTP. It is reasonable to suggest that strings are involved in TTP pathogenesis; VWF strings are found in mice deficient in Adamts13 that also suffer from TTP. In addition, VWF strings bind platelets and the thrombi seen in TTP are made primarily of VWF and platelets. However, whether or not VWF strings are sufficiently prothrombotic to form occlusive thrombi is yet to be seen. VWF strings may be a very important part of the TTP puzzle, and if they do prove to be important in TTP, they may provide an important drug target for TTP therapy.
In this thesis, I will provide insight into the potential mechanism of action of VWF in TTP. We have identified glycerol as a string-generating agent that functions similarly to histamine in vitro. Injecting these same agents into TTP-susceptible mice triggers TTP similarly to shigatoxin. Finally, we identified conditions in vitro that form dense VWF networks utilizing glycerol in calcium free buffer. These networks are far denser than any VWF string previously identified. If these structures can form in vivo, we believe that they are likely to be involved in the formation of the VWF and platelet rich thrombi formed seen in TTP.
: ENDOTHELIAL AGONISTS SIMULATE VWF RELEASE IN VITRO AND CHAPTER II

TRIGGER TTP IN VIVO
Introduction
Since the discovery of VWF strings (5), scientists have hypothesized that strings are involved in TTP pathogenesis. One of the most debated topics is whether or not VWF strings have physiological relevance in TTP (2) . That is to say, is there a process by which VWF strings can coalesce, bind platelets, and form occlusive thrombi?
Shigatoxin has been identified as an agent that can both induce VWF strings in vitro (24) and acutely trigger TTP in mice (8, 23) . It is believed that shigatoxin triggers TTP by causing large-scale endothelial activation, resulting in bulk secretion of VWF. Without functional ADAMTS13, VWF strings remain attached to the endothelial surface in vitro, and can bind numerous platelets (1, 5, 25) . It is hypothesized that aberrant association of VWF coupled with platelet binding leads to the occlusive thrombi seen in TTP patients (2, 22, 26) . This hypothesis has never been directly tested, possibly due to a lack of adequate in vivo imaging techniques as a result of the thickness of the tissues involved (primarily brain, heart, and kidneys) (9, 18, 19) .
The work described in this chapter demonstrates that, cells treated with glycerol generate VWF strings similarly to those treated with the known endothelial agonists histamine and shigatoxin. In addition, we show that TTP-susceptible mice, following injection of either glycerol or histamine, develop TTP-like manifestations similar to mice injected with shigatoxin (8) . Finally, we identify specific conditions in vitro that form dense networks of VWF.
Methods
Maintenance of HUVECs
Human umbilical vein endothelial cells (HUVECs) were acquired from ATCC. Cells were maintained in EGM-2 complete media (Lonzo), with media changed every other day. Cells were plated on glass coverslips coated with 2% gelatin (type a, Fisher Scientific) and grown to confluence for use in a parallel plate flow chamber.
Parallel Plate Flow Chamber
Coverslips of confluent HUVECs had their media removed and were treated with 3ml of one of the following four treatments: PBS containing calcium (Gibco), PBS containing calcium and 100 µM histamine (Sigma), PBS containing calcium and 10% glycerol (Research Products International Corporation) or PBS lacking calcium and containing 10% glycerol. The treatment remained on the cells for ten minutes, after which the coverslip was loaded into a Warner RC-31 flow chamber (Warner Instruments). The cells were then perfused with a rabbit, anti-human VWF antibody (Dako, 1:1000 dilution) for 10 minutes. The cells were then perfused with an Alexa 488 goat anti-rabbit IgG (Invitrogen) for 10 minutes. The cells were then perfused with buffer for 10 minutes to rinse out any remaining antibody. Following washout, images were collected using an Olympus DP-71 microscope equipped with fluorescence. Seven to ten random fields of view were collected from each independent experiment to be utilized for quantification.
Image Quantification and Statistical Analysis
Images were quantified using ImageJ. The percentage of each field that stained positive for VWF was determined to serve as a metric for density of VWF in each image. At least seven images from at least three independent experiments were utilized for each condition examined.
Each image was transformed to greyscale in Image J, then thresholding was used to determined the amount of each field positive for VWF. The area of the image positive for VWF was compared to the total area of the image to determine the percent of each field positive for VWF.
Data were compared using unpaired two-way t-tests between each treatment group
Animal Maintenance and Generation
Adamts13 -/-mice were generated as previously described (8) 
TTP Experiments
Two separate series of experiments were conducted: (1) all mice were injected intraperitoneally with 200µL 50% glycerol solution in PBS and (2) all mice were injected with 10 µL/g body weight 10 mM histamine in PBS. It is important to note that glycerol was administered once and histamine was administered every 24 hours before daily blood collection.
Prior to injection, 20µl blood samples were collected via retro-orbital eye bleed into EDTA-lined capillary tubes for complete blood count analysis using an Advia 120 Hematology Analyzer (Siemens). Samples were diluted 1:10 in PBS containing 5% BSA.
After injection, blood samples were collected every 24 hours for 4 days after the initial injection (5 days for total experiment length), and mice were visually monitored for agonal behavior. After the final CBC collection, all mice were sacrificed and perfusion fixed using ZFix buffered formalin. Brains, kidneys, and hearts were collected for histological analysis.
Histological Analysis
All tissues collected from TTP experiments were processed in the University of Iowa Histological Research Core. Serial sections were taken at several depths from each tissue and stained with either hematoxylin and eosin or anti-VWF immunohistochemistry with a hematoxylin counterstain in order to identify VWF rich thrombi. Slides were viewed using standard light microscopy techniques. Images were collected based analogous regions between H&E and anti-VWF IHC slides that were positive for VWF thrombi.
CBC Data Analysis
Daily CBC data including platelet count were monitored daily. Mice that presented with thrombocytopenia on their baseline CBC were excluded. Daily platelet counts were calculated as a percent of baseline in order to account for baseline platelet variations between mice. In the glycerol-and histamine-injected groups, all mice not showing signs of TTP via CBC analysis were excluded from the data set.
Blood Smears
Before sacrifice at the end of the experiment, a final blood sample was collected to generate blood smears. Smears were allowed to dry, and were then stained using a HEMA 3 Kit (Fischer Scientific). Smears were viewed under light microscopy at 100x to look for schistocytes. 
Division of Labor
Results
Histamine and glycerol form VWF strings in vitro
Glycerol and calcium free buffer form VWF networks.
Further screening revealed that 10% glycerol in a calcium free buffer was far more potent than glycerol alone ( Figure II.7) . The dense networks generated by the combination of glycerol and calcium-free buffer are far thicker and longer than previously described VWF strings (2, 5, 6, 15, 25, 27-30). These networks are 35-70µm thick via confocal microscopy (data not shown) and are capable of coalescing into fibers that can be as long as several millimeters (Figure II.7) .
Discussion
We sought to determine whether or not administering agents known to trigger VWFsecretion in vitro would also trigger TTP in TTP-susceptible mice in vivo. We reasoned that if agents that promote the formation of strings in vitro also trigger TTP in vivo, then the two events may be related. It is reasonable to hypothesize that the two would be related: VWF strings form in vitro in the presence of plasma from TTP patients but not in the presence of plasma from healthy donors (5) . VWF strings are capable of binding multiple platelets (5); the thrombi seen in TTP are known to be VWF-and platelet-rich (9, 11) . VWF strings were not identified in vivo until the Adamts13-/-mouse was generated as a model of TTP (8) . In addition, using the same mouse model, it was shown that VWF is necessary for TTP (23) . It is also known that shigatoxin triggers both VWF strings in vitro (24) and TTP in vivo (8) . However, directly relating TTP and VWF strings has proved difficult because of the technical challenges associated with direct visualization of VWF and platelets in thick tissues, in real time, and in vivo. Our methodology provides a way to build a body of evidence to support our hypothesis until these technical challenges can be overcome. In the aforementioned series of experiments, we determined that glycerol, like histamine, forms VWF strings in vitro and both trigger TTP in vivo, supporting our hypothesis that VWF strings and TTP are likely related.
It has not been previously demonstrated that VWF strings could coalesce into any sort of thick meshwork, which makes our finding of glycerol-induced dense VWF networks in vitro There may also be more to the role of VWF in TTP than which specific pool of VWF is most important. With ADAMTS13 deficiency, there is a characteristic upward shift in VWF multimer size that is seen following VWF multimer gel analysis (8, 9, 14, 18, 31) , resulting in larger species of VWF, dubbed ultra-large VWF (UL-VWF). UL-VWF is believed to play a roll in TTP and may be involved in the formation of occlusive thrombi. Besides this welldocumented upward shift of the VWF multimer distribution, ADAMTS13 deficiency also results in loss of the smallest forms of VWF, which has not been as well studied. These smaller forms would still be able to bind all (or most) of the same targets as the larger forms of VWF, but it is unlikely that they would be able to participate in the formation of VWF strings or networks. This it is possible that these smaller VWF multimers prevent the pathologic association of VWF by serving as a scavenger, binding larger forms of VWF and preventing them from associating with other large VWF multimers or VWF binding partners on the endothelial surface. The loss of ADAMTS13 function in TTP could also result in the loss of these small VWF multimers, leading to the pathologic association of larger VWF multimers and ultimately to thrombosis. If this is the case, with reconstitution of the smaller forms of VWF, it may be possible to ameliorate TTP disease severity by restoring this regulatory element.
The overall contribution of this work to the field is new insight into the importance of VWF strings in TTP. While VWF strings are widely studied, there is little direct evidence to show if or how they are involved in TTP. This thesis provides evidence to suggest that those agents which form strings in vitro also trigger acute TTP in TTP-susceptible mice. This implies a possible relationship between the two events, one that is likely mediated by endothelial secretion of VWF strings. A well-supported mechanism for the formation of thrombi in TTP would likely provide a wealth of targets for future pharmaceuticals. If a small molecule inhibitor could be designed to prevent the pathologic association of VWF string formation in TTP patients it is likely that the formation of occlusive thrombi could be prevent or reversed, with potential amelioration of disease symptoms. As discussed above, low molecular weight VWF multimers (or possibly even VWF monomers) could also be investigated as potential therapeutic agent for TTP. Figure I .1 were quantified, and VWF network density was measured as a percent of each field that labeled positive for VWF. Quantification was performed on seven random fields from each of three biologic replicates. Image J was used to assess the percent of each field staining positive for VWF. Statistical significance was determined based on an unpaired student's t-test, with pvalues listed above each group compared. If no p-value is listed, no statistical significance was determined. A. HUVECs treated with 10% glycerol in calcium free buffer for ten minutes generated dense VWF networks. These networks are very dense and cover the majority of the coverslip. B. A compilation of low power images across the length of a coverslip to demonstrate a large VWF fiber among the dense VWF networks following glycerol in calcium free buffer treatment. Yellow bar represents 2.7mm.
: FUTURE DIRECTIONS CHAPTER III
As mentioned in the previous chapter, direct visualization of the formation of TTP thrombi will provide essential information for the TTP disease model. Typically these thrombi occur most commonly in microvessels of thick, opaque tissue (brain, heart, and kidney (9, 11) ). However, it may be possible to trigger VWF thrombi in larger blood vessels (such as mesenteric venules) that are accessible via intravital microscopy. By fluorescently labeling platelets, it might be possible to indirectly identify VWF strings in vivo. We hypothesize that agents that form strings in vitro and trigger TTP in vivo will also form strings or thrombi in vivo visible by intravital microscopy. Using this technique, it would be possible to assess the in vivo thrombotic potential of glycerol and calcium-free buffer in vivo. It is extremely difficult to replicate 10% glycerol in a calcium-free environment in vivo, so local administration of glycerol and EDTA during intravital microscopy may provide an alternative method.
Our identification of VWF networks leads us to believe that endothelial VWF is likely critical in TTP. However, directly assessing this hypothesis in vivo would be very technically challenging. To isolate endothelial VWF, a bone marrow transplant from Vwf -/-mice would have to be given to Vwf +/+ or +/-mice, so that only endothelial cells would contain VWF.
However, endothelial cells would continue to secrete VWF into circulation (plasma VWF).
Unless secretion of endothelial VWF could be temporally controlled until the beginning of a TTP experiment, endothelial VWF could not be truly isolated.
It would be possible to generate mice containing only plasma VWF or only platelet VWF. Isolating plasma VWF is possible by hydrodynamic tail vein (HTV) injection of a Vwf -/-mouse with a murine VWF construct cloned into a pLive vector. HTV delivery of this construct generates a mouse that transiently expresses VWF in liver hepatocytes that is subsequently secreted into circulation, resulting in only plasma VWF. Platelet VWF can be reconstituted by performing a bone marrow transplant from a Vwf +/-or +/+ mouse into a Vwf -/-mouse. Both of these experiments are ongoing projects in the lab. Preliminary experiments reconstituting plasma-only VWF have demonstrated that Vwf -/-mice that have been HTV injected with a pLive murine VWF construct do not form VWF string (Figure III.1) . Based on these data, we would hypothesize that these same mice would not present with TTP following shigatoxin injection, further building a case for the involvement of VWF strings in TTP. While determining which pool or pools of VWF are necessary and sufficient for TTP is a challenging task, it will undoubtedly provide essential data for a more complete disease model for TTP. Each particular pool has a specific and very different set of interactions that would drastically alter the direction of research and therapeutics. For example, if it is determined that plasma VWF is, in fact, necessary and sufficient for TTP, the interactions of VWF with other plasma proteins could play a part in altering disease severity. Moreover, sheer stress folding and unfolding of large VWF multimers in circulation may also be important. In this case, to specifically target pharmaceuticals, it would be important to tailor them to effect plasma VWF but not necessarily platelets or endothelial cells. If platelet VWF is the critical pool, studying α-granule trafficking and secretion would be critical for advancing the disease model. Platelet-targeted drugs would likely play an important part in treating the disease, perhaps by inhibiting α-granule release. If our original hypothesis (that endothelial VWF is most important in TTP) is correct, studying VWF release in TTP could provide important information into the formation of TTP thrombi and drugs that curb endothelial secretion of Weibel-Palade bodies could ameliorate disease severity and reverse symptoms. In order to effectively target specific "designer" therapeutics for TTP, we need to know how to tailor them to best suit the disease. Preliminary intravital experiments suggest that plasma VWF is insufficient for the formation of VWF strings in vivo. Three mice were utilized for this experiment: Vwf +/-Adamts13 -/-transfected with a control plasmid (positive control), Vwf -/-Adamts13 -/-mice transfected with a control plasmid (negative controls) and Vwf -/-Adamts13 -/-transfected with pLive mVWF. Platelets were labeled via retro-orbital injection of rhodamine. Mice were anesthetized and their mesenteric venules were surgically exposed and exposed to 100µL of 10mM calcium ionophore A32187 in order to form VWF strings as previously described (8) . VWF +/-Adamts13 -/-transfected with a control plasmid demonstrated the formation of VWF strings (arrows) while Vwf -/-Adamts13 -/-mice transfected with a control plasmid (negative controls) and VWF -/-Adamts13 -/-transfected with pLive mVWF did not. All images are stills collected from the videos. Each group is N=1. 
